Related Experiment Video

Updated: Jul 15, 2026

A Simple Guide Screw Method for Intracranial Xenograft Studies in Mice
08:11

A Simple Guide Screw Method for Intracranial Xenograft Studies in Mice

Published on: September 26, 2011

23.1K

Unlocking Hope: Anti-VEGFR inhibitors and their potential in glioblastoma treatment

Ali Berro1, Ahmad Assi1, Mohamad Farhat1

  • 1Hematology-Oncology Department, Hôtel-Dieu de France University Hospital, Saint Joseph University of Beirut, Beirut, Lebanon.

Critical Reviews in Oncology/Hematology
|April 27, 2024
PubMed
Abstract

Insights

Vascular Endothelial Growth Factor Receptor (VEGFR) is a promising target for glioblastoma multiforme (GBM) treatment. Anti-VEGFR tyrosine kinase inhibitors (TKIs) show potential, but further research is needed for optimal efficacy and safety.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Glioblastoma multiforme (GBM) is an aggressive brain tumor with limited treatment options.
  • Vascular Endothelial Growth Factor Receptor (VEGFR) signaling plays a critical role in GBM pathogenesis and progression.
  • VEGFR gene mutations and protein expression are implicated in GBM development.

Purpose of the Study:

  • To systematically review the evidence on VEGFR gene mutations and protein expression in GBM.
  • To evaluate the efficacy and safety of anti-VEGFR tyrosine kinase inhibitors (TKIs) for GBM treatment.

Main Methods:

  • Comprehensive literature search of PubMed up to August 2023.
  • Utilized Boolean operators and MeSH term "glioma" with VEGFR-related keywords.
  • Systematic review and synthesis of relevant studies.

Main Results:

  • VEGFR expression correlates with glioma grade and GBM progression, indicating its therapeutic relevance.
  • Regorafenib and axitinib demonstrate promise as anti-VEGFR TKIs for GBM.
  • Challenges include blood-brain barrier penetration and toxicity; combination therapies and enhanced delivery strategies may improve outcomes.

Conclusions:

  • Anti-VEGFR therapies show promise for GBM treatment.
  • Future research should focus on personalized medicine, biomarker-guided selection, and innovative strategies to overcome treatment challenges.
  • Improving patient quality of life is a key consideration for future research.
Keywords:
AngiogenesisBrain tumorsGlioblastomaTKIsVEGFR

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.4K
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.